Taxane chemotherapy for hormone-naïve prostate cancer with its expanding role as breakthrough strategy

Frontiers in Oncology

Volumn 5, Issue JAN, 2016, Pages

  Shiota, Masaki ^a   Yokomizo, Akira ^a   Eto, Masatoshi ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Androgen deprivation therapy; Cabazitaxel; Castration resistant prostate cancer; Docetaxel; Hormone na ve prostate cancer

Indexed keywords

ABIRATERONE ACETATE; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; ESTRAMUSTINE; ETOPOSIDE; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; TAXANE DERIVATIVE;

ANDROGEN DEPRIVATION THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; SHORT SURVEY;

EID: 84958213594     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00304     Document Type: Short Survey

References (23)

1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 351:1502-12. doi: 10.1056/NEJMoa040720
2. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 351:1513-20. doi:10.1056/NEJMoa041318
3. Shiota M, Yokomizo A, Fujimoto N, Kuruma H, Naito S. Castration-resistant prostate cancer: novel therapeutics pre-or post-taxane administration. Curr Cancer Drug Targets (2013) 13:444-59. doi:10.2174/15680096113139990078
4. Eigl BJ, Eggener SE, Baybik J, Ettinger S, Chi KN, Nelson C, et al. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin Cancer Res (2005) 11:4905-11. doi:10.1158/1078-0432.CCR-04-2140
5. Fizazi K, Sikes CR, Kim J, Yang J, Martinez LA, Olive MC, et al. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer. Anticancer Res (2004) 24:2897-903.
6. Shiota M, Kashiwagi E, Yokomizo A, Takeuchi A, Dejima T, Song Y, et al. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor. Prostate (2013) 73:1336-44. doi:10.1002/pros.22681
7. Marín-Aguilera M, Codony-Servat J, Reig O, Lozano JJ, Fernández PL, Pereira MV, et al. Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer. Mol Cancer Ther (2014) 13:1270-84. doi:10.1158/1535-7163.MCT-13-0775
8. Puhr M, Hoefer J, Schäfer G, Erb HH, Oh SJ, Klocker H, et al. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am J Pathol (2012) 181:2188-201. doi:10.1016/j.ajpath.2012.08.011
9. Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol (2013) 14:149-58. doi:10.1016/S1470-2045(12)70560-0
10. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med (2015) 373:737-46. doi:10.1056/NEJMoa1503747
11. James ND, Sydes MR, Mason MD, Clarke NW, Anderson J, Dearnaley DP, et al. Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: first overall survival results from STAMPEDE (NCT00268476). J Clin Oncol (2015) 33(Suppl):5001.
12. Fizazi K, Jenkins C, Tannock IF. Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. Ann Oncol (2015) 26:1660-7. doi:10.1093/annonc/mdv245
13. Tucci M, Bertaglia V, Vignani F, Buttigliero C, Fiori C, Porpiglia F, et al. Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer: a systematic review and meta-analysis. Eur Urol (2015). doi:10.1016/j.eururo.2015.09.013
14. Sonpavde G, Bhor M, Hennessy D, Bhowmik D, Shen L, Nicacio L, et al. Sequencing of cabazitaxel and abiraterone acetate after docetaxel in metastatic castration-resistant prostate cancer: treatment patterns and clinical outcomes in multicenter community-based US oncology practices. Clin Genitourin Cancer (2015) 13:309-18. doi:10.1016/j.clgc.2014.12.019
15. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (2010) 376:1147-54. doi:10.1016/S0140-6736(10)61389-X
16. Fizazi K, Abrahamsson PA, Ahlgren G, Bellmunt J, Castellano D, Culine S, et al. Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in Europe. Eur Urol (2015) 67:904-12. doi:10.1016/j.eururo.2014.08.076
17. DorffTB, Flaig TW, Tangen CM, Hussain MH, Swanson GP, Wood DP Jr, et al. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol (2011) 29:2040-5. doi:10.1200/JCO.2010.32.2776
18. Cha EK, Eastham JA. Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer. Urol Oncol (2015) 33:217-25. doi:10.1016/j.urolonc.2014.11.020
19. ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/home
20. Fizazi K, Lesaunier F, Delva R, Gravis G, Rolland F, Priou F, et al. A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial. Eur J Cancer (2012) 48:209-17. doi:10.1016/j.ejca.2011.10.015
21. Fizazi K, Faivre L, Lesaunier F, Delva R, Gravis G, Rolland F, et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncol (2015) 16:787-94. doi:10.1016/S1470-2045(15)00011-X
22. Sandler HM, Hu C, Rosenthal SA, Sartor O, Gomella LG, Amin M, et al. A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521). J Clin Oncol (2015) 33(Suppl):5002.
23. Kellokumpu-Lehtinen PL, Hjälm-Eriksson M, Thellenberg-Karlsson C, Åström L, Franzen L, Marttila T, et al. Toxicity in patients receiving adjuvant docetaxel + hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial. Prostate Cancer Prostatic Dis (2012) 15:303-7. doi:10.1038/pcan.2012.13